GM-CSF autoantibodies and neutrophil dysfunction in pulmonary alveolar proteinosis

New England Journal of Medicine

Volumn 356, Issue 6, 2007, Pages 567-579

  Uchida, Kanji ^a   Beck, David C ^b   Yamamoto, Takashi ^a   Berclaz, Pierre Yves ^a   Abe, Shuichi ^a   Staudt, Margaret K ^a   Carey, Brenna C ^a   Filippi, Marie Dominique ^a   Wert, Susan E ^a   Denson, Lee A ^a   Puchalski, Jonathan T ^a,b   Hauck, Diane M ^a   Trapnell, Bruce C ^a,b  

^a CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER   (United States)

^b UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AUTOANTIBODY; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR ANTIBODY; UNCLASSIFIED DRUG;

ADOLESCENT; ADULT; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIMICROBIAL ACTIVITY; ARTICLE; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; CYSTIC FIBROSIS; FEMALE; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; KIDNEY FAILURE; LUNG ALVEOLUS PROTEINOSIS; MALE; MOUSE; MOUSE STRAIN; NEUTROPHIL; NONHUMAN; PRIORITY JOURNAL; ULTRASTRUCTURE; WILD TYPE;

EID: 33846889015     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMoa062505     Document Type: Article

References (37)

1. Rosen SH, Castleman B, Liebow AA. Pulmonary alveolar proteinosis. N Engl J Med 1958;258:1123-42.
2. Seymour JF, Presneill JJ. Pulmonary alveolar proteinosis: progress in the first 44 years. Am J Respir Crit Care Med 2002;166:215-35.
3. Trapnell BC, Whitsett JA, Nakata K. Pulmonary alveolar proteinosis. N Engl J Med 2003;349:2527-39.
4. Kitamura T, Tanaka N, Watanabe J, et al. Idiopathic pulmonary alveolar proteinosis as an autoimmune disease with neutralizing antibody against granulocyte/macrophage colony-stimulating factor. J Exp Med 1999;190:875-80.
5. Uchida K, Nakata K, Trapnell BC, et al. High-affinity autoantibodies specifically eliminate granulocyte-macrophage colonystimulating factor activity in the lungs of patients with idiopathic pulmonary alveolar proteinosis. Blood 2004;103:1089-98.
6. Shibata Y, Berclaz PY, Chroneos ZC, Yoshida M, Whitsett JA, Trapnell BC. GM-CSF regulates alveolar macrophage differentiation and innate immunity in the lung through PU.1. Immunity 2001;15:557-67.
7. Stanley E, Lieschke GJ, Grail D, et al. Granulocyte/macrophage colony-stimulating factor-deficient mice show no major perturbation of hematopoiesis but develop a characteristic pulmonary pathology. Proc Natl Acad Sci U S A 1994;91:5592-6.
8. Dranoff G, Crawford AD, Sadelain M, et al. Involvement of granulocyte-macrophage colony-stimulating factor in pulmonary homeostasis. Science 1994;264:713-6.
9. Ikegami M, Ueda T, Hull W, et al. Surfactant metabolism in transgenic mice after granulocyte macrophage-colony stimulating factor ablation. Am J Physiol 1996;270:L650-L658.
10. Bonfield TL, Raychaudhuri B, Malur A, et al. PU.1 regulation of human alveolar macrophage differentiation requires granulocyte-macrophage colony-stimulating factor. Am J Physiol Lung Cell Mol Physiol 2003;285:L1132-L1136.
11. Seymour JF, Presneill JJ. Pulmonary alveolar proteinosis: what is the role of GM-CSF in disease pathogenesis and treatment? Treat Respir Med 2004;3:229-34.
12. Seymour JF, Lieschke GJ, Grail D, Quilici C, Hodgson G, Dunn AR. Mice lacking both granulocyte colony-stimulating factor (CSF) and granulocyte-macrophage CSF have impaired reproductive capacity, perturbed neonatal granulopoiesis, lung disease, amyloidosis, and reduced long-term survival. Blood 1997;90:3037-49.
13. Gonzalez-Juarrero M, Hattle JM, Izzo A, et al. Disruption of granulocyte macrophage-colony stimulating factor production in the lungs severely affects the ability of mice to control Mycobacterium tuberculosis infection. J Leukoc Biol 2005;77:914-22.
14. Zhan Y, Lieschke GJ, Grail D, Dunn AR, Cheers C. Essential roles for granulocyte-macrophage colony-stimulating factor (GM-CSF) and G-CSF in the sustained hematopoietic response of Listeria monocytogenes-infected mice. Blood 1998;91:863-9.
15. Condliffe AM, Kitchen E, Chilvers ER. Neutrophil priming: pathophysiological consequences and underlying mechanisms. Clin Sci (Lond) 1998;94:461-71.
16. Fleischmann J, Golde DW, Weisbart RH, Gasson JC. Granulocyte-macrophage colony-stimulating factor enhances phagocytosis of bacteria by human neutrophils. Blood 1986;68:708-11.
17. Graves V, Gabig T, McCarthy L, Strour EF, Leemhuis T, English D. Simultaneous mobilization of Mac-1 (CD11b/CD18) and formyl peptide chemoattractant receptors in human neutrophils. Blood 1992;80:776-87. [Erratum, Blood 1993;81:1668.]
18. Clark RA, Nauseef WM. Isolation and functional analysis of neutrophils. In: Bierer B, Coligan JE, Margulies DH, Shevach EM, Strober W, eds. Current protocols in immunology. New York: John Wylie, 2005:2-6.
19. Berclaz PY, Zsengeller Z, Shibata Y, et al. Endocytic internalization of adenovirus, nonspecific phagocytosis, and cytoskeletal organization are coordinately regulated in alveolar macrophages by GM-CSF and PU.1. J Immunol 2002;169:6332-42.
20. Bainton DF, Ullyot JL, Farquhar MG. The development of neutrophilic polymorphonuclear leukocytes in human bone marrow. J Exp Med 1971;134:907-34.
21. Berclaz PY, Shibata Y, Whitsett JA, Trapnell BC. GM-CSF, via PU.1, regulates alveolar macrophage Fcgamma R-mediated phagocytosis and the IL-18/IFN-gamma-mediated molecular connection between innate and adaptive immunity in the lung. Blood 2002;100:4193-200.
22. Hassan NF, Campbell DE, Douglas SD. Phorbol myristate acetate induced oxidation of 2′,7′-dichlorofluorescin by neutrophils from patients with chronic granulomatous disease. J Leukoc Biol 1988;43:317-22.
23. DeForge LE, Billeci KL, Kramer SM. Effect of IFN-gamma on the killing of S. aureus in human whole blood: assessment of bacterial viability by CFU determination and by a new method using alamar-Blue. J Immunol Methods 2000;245:79-89.
24. Boxio R, Bossenmeyer-Pourie C, Steinckwich N, Dournon C, Nusse O. Mouse bone marrow contains large numbers of functionally competent neutrophils. J Leukoc Biol 2004;75:604-11.
25. Rosenzweig SD, Holland SM. Phagocyte immunodeficiencies and their infections. J Allergy Clin Immunol 2004;113:620-6.
26. Meager A, Wadhwa M, Bird C, et al. Spontaneously occurring neutralizing antibodies against granulocyte-macrophage colony-stimulating factor in patients with autoimmune disease. Immunology 1999;97:526-32.
27. Roberts AW. G-CSF: a key regulator of neutrophil production, but that's not all! Growth Factors 2005;23:33-41.
28. Treweeke AT, Aziz KA, Zuzel M. The role of G-CSF in mature neutrophil function is not related to GM-CSF-type cell priming. J Leukoc Biol 1994;55:612-6.
29. Hellmich B, Csernok E, Schatz H, Gross WL, Schnabel A. Autoantibodies against granulocyte colony-stimulating factor in Felty's syndrome and neutropenic systemic lupus erythematosus. Arthritis Rheum 2002;46:2384-91.
30. Iwasaki H, Somoza C, Shigematsu H, et al. Distinctive and indispensable roles of PU.1 in maintenance of hematopoietic stem cells and their differentiation. Blood 2005;106:1590-600.
31. Guthridge MA, Powell JA, Barry EF, et al. Growth factor pleiotropy is controlled by a receptor Tyr/Ser motif that acts as a binary switch. EMBO J 2006;25:479-89.
32. Rosenbloom AJ, Linden PK, Dorrance A, Penkosky N, Cohen-Melamed MH, Pinsky MR. Effect of granulocyte-monocyte colony-stimulating factor therapy on leukocyte function and clearance of serious infection in nonneutropenic patients. Chest 2005;127:2139-50.
33. Krinner EM, Raum T, Petsch S, et al. A human monoclonal IgG1 potently neutralizing the pro-inflammatory cytokine GM-CSF. Mol Immunol 2007;44:916-25.
34. Mann BS, Chung KF. Blood neutrophil activation markers in severe asthma: lack of inhibition by prednisolone therapy. Respir Res 2006;7:59.
35. Koller DY, Urbanek R, Gotz M. Increased degranulation of eosinophil and neutrophil granulocytes in cystic fibrosis. Am J Respir Crit Care Med 1995;152:629-33.
36. Rivkind AI, Siegel JH, Littleton M, et al. Neutrophil oxidative burst activation and the pattern of respiratory physiologic abnormalities in the fulminant post-traumatic adult respiratory distress syndrome. Circ Shock 1991;33:48-62.
37. Bozinovski S, Jones J, Beavitt SJ, Cook AD, Hamilton JA, Anderson GP. Innate immune responses to LPS in mouse lung are suppressed and reversed by neutralization of GM-CSF via repression of TLR-4. Am J Physiol Lung Cell Mol Physiol 2004;286:L877-L885.